1.4 million cardiac leads are implanted every year. When they fail or get infected, removing them risks cardiac tamponade, vascular tears, and death. No manufacturer designs leads for safe extraction. We do.
10,000-15,000 lead extractions are performed in the US every year. 1.46% result in cardiac tamponade — and when tamponade occurs, mortality reaches 20-31%. The procedure hasn't fundamentally changed in decades.
Within months of implantation, scar tissue encases the lead body, bonding it to vessel walls and cardiac tissue. Median dwell time at extraction: 7.4 years. The longer the lead stays, the more dangerous removal becomes.
1.46% of extractions cause cardiac tamponade requiring emergency intervention. Cardiac avulsion carries 20% mortality; vascular avulsion reaches 31.6%. Even at expert centers, the in-hospital death rate is 0.28%.
When extraction is too risky, leads are abandoned in situ. 17-25% of CIED patients carry at least one abandoned lead, causing venous obstruction, tricuspid regurgitation, and complicating every future procedure.
Lead extraction requires specialized centers, surgical teams, and hybrid OR standby. Average procedure cost: $35,000-$50,000. The extraction market approaches $920M annually — all spent managing a preventable design problem.
Published clinical data from large registries and multicenter trials paint a clear picture: lead extraction remains high-risk, and the problem is growing.
Of all lead extractions result in cardiac tamponade requiring emergency intervention — the most feared complication. Cardiac avulsion carries 20% mortality; vascular avulsion reaches 31.6%.
When cardiac tamponade occurs during extraction, mortality ranges from 20% (cardiac avulsion) to 31.6% (vascular avulsion). These patients require emergent sternotomy.
Only 10,000-15,000 lead extractions are performed annually in the US — vs. 500,000+ implants. Many leads that should come out never do because the risk is too high.
Lead dwell time is the strongest predictor of extraction difficulty. Every year a lead remains implanted, fibrotic adhesions intensify, making extraction more dangerous and less likely to succeed.
Current extraction technology (laser sheaths, mechanical dilator sheaths, and rotational tools) addresses fibrosis after it forms. RetractCor's approach prevents the adhesion cascade from the start.
We analyzed the top 5 cardiac lead companies. They build leads to stay in. They build tools to get them out. Nobody builds leads that come out safely by design.
This is not a tooling problem. It's a design problem. And no one in a $20B CRM market is solving it — because the same companies selling leads also sell the $920M in extraction tools needed to remove them.
The Big 3 are investing in leadless pacemakers to eliminate leads entirely. But leadless only covers single/dual-chamber pacing — 600K+ patients annually still need traditional leads for CRT and ICD therapy.
Leaving leads behindThe extraction tool market treats removal as an inevitable surgical challenge. Their approach: build sharper sheaths and stronger stylets. They assume leads will always be hard to remove.
Reactive, not preventiveWe're the only company designing cardiac leads for safe extraction from the start. Anti-fibrotic surfaces and a controlled retraction mechanism eliminate the need for powered extraction tools.
Design-first approachCurrent cardiac leads are engineered to stay in forever. But patients outlive their devices, infections happen, and technology improves. RetractCor starts with a different premise: every lead should be safely removable.
Instead of building better extraction tools for leads that resist removal, we're building leads that don't resist removal in the first place.
Cardiac leads are a massive, growing market. But the industry has optimized for implantation, not the full device lifecycle.
The global market for implantable cardiac leads, growing at 5.2% CAGR driven by aging populations and expanding CRM indications. Every lead implanted today will eventually need management or removal.
Spent annually on tools, procedures, and specialized centers dedicated to removing leads that weren't designed to come out. A market that exists only because of a design problem.
Annual patients receiving multi-chamber CRT or ICD leads that cannot be replaced by leadless technology. These patients need leads, and those leads need to be extractable.
Estimated percentage of implanted leads that will require intervention (extraction, revision, or abandonment) within the device's functional lifetime, based on 15-year follow-up data.
We've mapped the regulatory journey. The 510(k) pathway allows us to demonstrate substantial equivalence to an already-cleared predicate device, avoiding the years-long PMA process.
Compared to 3-5 years for PMA, the 510(k) pathway allows us to leverage established predicate devices. Bench testing (not clinical trials) typically suffices for substantial equivalence.
Gold-standard active fixation lead with 20+ years of clinical data, 1.6% malfunction rate at 5 years, and proven safety profile. Direct comparison for substantial equivalence arguments.
File provisional patent to establish priority. Submit pre-submission meeting request to FDA to confirm testing strategy and clinical data requirements.
Electrical performance, mechanical durability, fixation retention, extraction force analysis. ISO 10993-1 biocompatibility testing.
Compile all test data, predicate comparison, risk analysis, and labeling. Submit to FDA.
FDA review period per MDUFA III. Typical 1-2 rounds of additional information requests.
Ready to build the future of cardiac lead design?
Interested in Partnering? Get in Touch →RetractCor was founded on a simple observation: if we know leads need to come out, why aren't we designing them for removal?
The cardiac rhythm management industry has spent decades optimizing lead fixation, conductor durability, and sensing performance. These are solved problems. What remains unsolved is the other end of the lifecycle: when the lead needs to be removed, upgraded, or replaced.
We're assembling a team of cardiac device engineers, electrophysiologists, and materials scientists focused exclusively on this problem. Our goal is to make lead extraction as routine as lead implantation.
Whether you're a cardiologist, device engineer, researcher, or potential partner, we'd like to hear from you. We're actively building our clinical advisory network and engineering team.
Leadless pacemakers solve part of the problem, but millions of patients still need traditional leads for complex cardiac therapy. RetractCor is building the leads those patients deserve.
Join the Mission →